Phage-antibiotic synergy against daptomycin-nonsusceptible MRSA in an ex vivo simulated endocardial pharmacokinetic/pharmacodynamic model
Antimicrobial Agents and Chemotherapy · 03.04.2024 · 68 (4)
DOI: 10.1128/aac.01388-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 03.04.2024. Verfasst von Ashlan J Kunz Coyne und 6 weiteren Autor:innen. Beteiligte Einrichtung: Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University…. Hauptthemen laut MEDLINE: Daptomycin, Methicillin-Resistant Staphylococcus aureus. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Phage-antibiotic combinations (PAC) offer a potential solution for treating refractory daptomycin-nonsusceptible (DNS) methicillin-resistant Staphylococcus aureus (MRSA) infections. We examined PAC activity against two well-characterized DNS MRSA strains (C4 and C37) in vitro and ex vivo . PACs comprising daptomycin (DAP) ± ceftaroline (CPT) and a two-phage cocktail (Intesti13 + Sb-1) were evaluated for phage-antibiotic synergy (PAS) against high MRSA inoculum (10 9 CFU/mL) using (i) modified checkerboards (CB), (ii) 24-h time-kill assays (TKA), and (iii) 168-h ex vivo simulated endocardial vegetation (SEV) models. PAS was defined as a fractional inhibitory concentration ≤0.5 in CB minimum inhibitory concentration (MIC) or a ≥2 log 10 CFU/mL reduction compared to the next best regimen in time-kill assays and SEV models. Significant differences between regimens were assessed by analysis of variance with Tukey’s post hoc modification (α = 0.05). CB assays revealed PAS with Intesti13 + Sb-1 + DAP ± CPT. In 24-h time-kill assays against C4, Intesti13 + Sb-1 + DAP ± CPT demonstrated synergistic activity (−Δ7.21 and −Δ7.39 log 10 CFU/mL, respectively) ( P < 0.05 each). Against C37, Intesti13 + Sb-1 + CPT ± DAP was equally effective (−Δ7.14 log 10 CFU/mL each) and not significantly different from DAP + Intesti13 + Sb-1 (−Δ6.65 log 10 CFU/mL). In 168-h SEV models against C4 and C37, DAP ± CPT + the phage cocktail exerted synergistic activities, significantly reducing bio-burdens to the detection limit [2 log 10 CFU/g (−Δ7.07 and −Δ7.11 log 10 CFU/g, respectively)] ( P < 0.001). At 168 h, both models maintained stable MICs, and no treatment-emergent phage resistance occurred with DAP or DAP + CPT regimens. The two-phage cocktail demonstrated synergistic activity against two DNS MRSA isolates in combination with DAP + CPT in vitro and ex vivo . Further in vivo PAC investigations are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
- The Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
- The Lundquist Institution for Biomedical Innovation at Harbor-UCLA, Torrance, California, USA.
- Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
- Department of Pharmacy Services, Detroit Receiving Hospital, Detroit Medical Center, Detroit, Michigan, USA.
- Division of Infectious Diseases, Department of Medicine, Wayne State University, Detroit, Michigan, USA.
ORCID-Profile: Ashlan J Kunz Coyne, Michael J Rybak
Förderung
- NIAID NIH HHS
Zitieren
APA
Kunz Coyne, A. J., Bleick, C., Stamper, K., Kebriaei, R., Bayer, A. S., Lehman, S. M., & Rybak, M. J. (2024). Phage-antibiotic synergy against daptomycin-nonsusceptible MRSA in an ex vivo simulated endocardial pharmacokinetic/pharmacodynamic model. Antimicrobial Agents and Chemotherapy, 68(4). https://doi.org/10.1128/aac.01388-23
Vancouver
Kunz Coyne AJ, Bleick C, Stamper K, Kebriaei R, Bayer AS, Lehman SM, et al. Phage-antibiotic synergy against daptomycin-nonsusceptible MRSA in an ex vivo simulated endocardial pharmacokinetic/pharmacodynamic model. Antimicrobial Agents and Chemotherapy. 2024;68(4). doi:10.1128/aac.01388-23
BibTeX
@article{KunzCoyne2024,
author = {Kunz Coyne, Ashlan J and Bleick, Callan and Stamper, Kyle and Kebriaei, Razieh and Bayer, Arnold S and Lehman, Susan M and Rybak, Michael J},
title = {Phage-antibiotic synergy against daptomycin-nonsusceptible MRSA in an ex vivo simulated endocardial pharmacokinetic/pharmacodynamic model},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
volume = {68},
number = {4},
doi = {10.1128/aac.01388-23}
}
EUVIMED